$2.31
1.70% yesterday
Nasdaq, Aug 11, 10:00 pm CET
ISIN
US23284F1057
Symbol
CTMX

CytomX Therapeutics, Inc. Stock price

$2.31
-0.11 4.55% 1M
+1.55 204.63% 6M
+1.28 124.27% YTD
+1.12 94.12% 1Y
+0.78 50.98% 3Y
-4.68 66.95% 5Y
-10.59 82.09% 10Y
-10.59 82.09% 20Y
Nasdaq, Closing price Mon, Aug 11 2025
-0.04 1.70%
ISIN
US23284F1057
Symbol
CTMX
Industry

Key metrics

Basic
Market capitalization
$381.0m
Enterprise Value
$301.1m
Net debt
positive
Cash
$79.9m
Shares outstanding
80.6m
Valuation (TTM | estimate)
P/E
4.8 | negative
P/S
2.6 | 4.2
EV/Sales
2.0 | 3.3
EV/FCF
negative
P/B
15.2
Financial Health
Equity Ratio
-0.4%
Return on Equity
-6,988.8%
ROCE
74.5%
ROIC
-240.1%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$147.6m | $90.0m
EBITDA
$37.7m | $6.1m
EBIT
$36.0m | $-24.1m
Net Income
$41.6m | $-17.5m
Free Cash Flow
$-81.5m
Growth (TTM | estimate)
Revenue
23.8% | -34.8%
EBITDA
192.8% | -77.1%
EBIT
232.3% | -196.6%
Net Income
151.7% | -154.8%
Free Cash Flow
11.7%
Margin (TTM | estimate)
Gross
-
EBITDA
25.5% | 6.8%
EBIT
24.4%
Net
28.2% | -19.4%
Free Cash Flow
-55.3%
More
EPS
$0.5
FCF per Share
$-1.0
Short interest
15.7%
Employees
120
Rev per Employee
$1.2m
Show more

Is CytomX Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,025 stocks worldwide.

CytomX Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a CytomX Therapeutics, Inc. forecast:

11x Buy
85%
2x Hold
15%

Analyst Opinions

13 Analysts have issued a CytomX Therapeutics, Inc. forecast:

Buy
85%
Hold
15%

Financial data from CytomX Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
148 148
24% 24%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 31 31
5% 5%
21%
- Research and Development Expense 80 80
2% 2%
54%
38 38
193% 193%
26%
- Depreciation and Amortization 1.69 1.69
17% 17%
1%
EBIT (Operating Income) EBIT 36 36
232% 232%
24%
Net Profit 42 42
152% 152%
28%

In millions USD.

Don't miss a Thing! We will send you all news about CytomX Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

CytomX Therapeutics, Inc. Stock News

Neutral
Seeking Alpha
3 days ago
CytomX Therapeutics, Inc. (NASDAQ:CTMX ) Q2 2025 Earnings Conference Call August 7, 2025 5:00 PM ET Company Participants Christopher W. Ogden - SVP & Chief Financial Officer Sean A.
Positive
Seeking Alpha
3 days ago
I remain bullish on CytomX Therapeutics due to promising pipeline developments in masked antibody-based immunotherapies for cancer. CX-2051 shows strong disease control in refractory colorectal cancer, with manageable side effects, supporting continued clinical progress. Initiation of CX-801 phase 1 trial in metastatic melanoma, combined with pembrolizumab, marks a key milestone for the pipeline.
Neutral
The Motley Fool
4 days ago
CytomX (CTMX) Q2 Revenue Drops 26%
More CytomX Therapeutics, Inc. News

Company Profile

CytomX Therapeutics, Inc. engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. Its pipeline includes immunotherapies, probody drug conjugates, T cell engaging bispecifics, and other multiple programs. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.

Head office United States
CEO Sean McCarthy
Employees 120
Founded 2010
Website cytomx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today